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Research  on  the  importance  of  lipoprotein(a)  [Lp(a)]  gained
new momentum  when  it  became  a  potential  therapeutic
target. Our  understanding  of  this  mysterious  circulating
lipoprotein particle  has  undergone  advances  and  setbacks
since its  discovery  in  1963  by  Kåre  Berg’s  group.1
Lp(a)  is  composed  of  liver-derived  apolipoprotein  A  and
apolipoprotein B-100,  and  has  a  similar  structure  to  both
low-density lipoprotein  cholesterol  (LDL-C)  and  plasmino-
gen. Lp(a)  thus  has  a  proatherogenic  and  a  prothrombotic
component, and  is  associated  with  the  pathogenesis  of  car-
diovascular disease  (CVD).
Findings  from  epidemiological,  genetic  and  clinical
studies2--4 have  provided  compelling  evidence  establishing
Lp(a) as  a  marker  of  increased  CVD  risk  in  both  primary  and
secondary prevention,  including  myocardial  infarction  (MI),
stroke, and  calcific  aortic  valve  disease  (CAVD).
However,  significant  gaps  in  knowledge  remain  about  the
biology and  pathophysiology  of  Lp(a).  To  address  these  gaps,
a National  Heart,  Lung,  and  Blood  Institute  working  group
identified several  challenges  to  fully  understand  the  role
of Lp(a)  in  CVD/CAVD.5 These  include  its  metabolism  and
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ion of  patients  at  high  Lp(a)-mediated  risk.
Joaquim  Menezes-Brandão  carried  out  a  single-center
etrospective observational  study,  published  in  this  issue  of
he Journal,6 of  516  patients  (224  male;  292  female;  98.6%
aucasian) with  at  least  two  cardiovascular  risk  factors  who
egularly attended  outpatient  consultations  at  a  cardiovas-
ular risk  and  metabolism  clinic  for  primary  prevention.
he aim  was  to  analyze  the  effect  of  combined  standard
harmacological therapy  along  with  lifestyle  interventions
or managing  Lp(a)  levels  in  patients  at  high  cardiovascular
isk but  who  had  not  suffered  major  adverse  cardiovas-
ular events.  The  patients  were  followed  for  a  mean  of
1.35±4.32 years.
The results  show  that,  in  this  well-controlled  population
nder different  drug  therapies  (statins,  angiotensin-
onverting enzyme  inhibitors,  angiotensin  receptor  block-
rs, oral  antidiabetics,  antiplatelets,  calcium  channel
lockers and  allopurinol)  there  was  a  reduction  in  Lp(a)
alues during  the  follow-up  period.
There  was  also  a  significant  association  between  Lp(a)
nd cardiovascular  risk  scores  in  patients  with  high  vas-
ular risk.  In  a  previous  work  in  the  same  population,7he  author  reported  that  increased  Lp(a)  levels  were  also
trongly associated  with  cardiovascular  risk  factors,  such  as
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arotid  intima-media  thickness,  LDL-C  and  homocysteine,  as
ell as  with  non-alcoholic  hepatic  steatosis.
This  study  points  to  the  need  to  measure  Lp(a)  in  routine
ssessment of  at-risk  patients,  because  as  a  marker  of  car-
iovascular risk,  Lp(a)  should  be  recognized  as  a  therapeutic
arget. It  may  be  useful  to  initiate  combined  drug  therapies
nd to  promote  healthy  lifestyles  in  primary  prevention,  tar-
eting various  cardiovascular  risk  factors,  in  order  to  delay
he atherosclerotic  process.
These  results  may  lead  to  better  identification  of  tar-
et populations  who  will  benefit  most  from  Lp(a)-lowering
herapies.
Several other  studies  have  addressed  this  question.
mong them,  the  BiomarCaRE  project8 confirmed  Lp(a)
s a  marker  of  cardiovascular  risk  in  the  European  pop-
lation, demonstrating  increased  cardiovascular  risk  for
p(a) >50  mg/dl,  which  is  in  line  with  the  target  level  of
50 mg/dl  recommended  by  the  guidelines.  Further,  it
howed a  north-south  gradient  of  Lp(a)  levels  across  Europe,
ith lower  levels  in  northern  European  cohorts.
Another  study  in  different  ethnic  groups  worldwide  also
howed that  high  Lp(a)  concentrations  (>50  mg/dl)  were
ssociated with  significantly  increased  risk  of  MI  in  all  pop-
lations except  Arabs  and  Africans.9
Nevertheless,  Lp(a)  is  not  routinely  tested  in  clinical
ractice, and  there  is  a  widespread  lack  of  awareness  of
ts role  in  accelerating  atherosclerotic  CVD.
Which  patient  groups  should  be  screened  for  Lp(a)?  The
uropean Atherosclerosis  Society  Consensus  Panel10 rec-
mmends that  Lp(a)  should  be  measured  in  patients  with
ntermediate or  high  risk  for  CVD  or  coronary  heart  dis-
ase (CHD).  In  particular,  those  patients  presenting  with
i) premature  CVD,  (ii)  familial  hypercholesterolemia,  (iii)
 family  history  of  premature  CVD  and/or  elevated  Lp(a),
iv) recurrent  CVD  despite  statin  treatment,  (v)  3%  10-year
isk of  fatal  CVD  according  to  the  European  guidelines11 and
vi) 10%  10-year  risk  of  fatal  and/or  non-fatal  CHD  according
o the  US  guidelines.  The  measurement  needs  to  be  taken
nly once  per  patient  life,  and  repeated  measurements  of
p(a) are  only  indicated  if  a  treatment  for  elevated  Lp(a)
evels is  initiated  in  order  to  monitor  therapeutic  response.12
Screening  for  elevated  Lp(a)  will  enable  standard  pre-
entative measures  to  be  introduced,  including  optimal
ontrol of  blood  pressure,  diabetes  and  LDL-C  levels  and
moking cessation,  and  in  the  future  the  use  of  novel
herapies that  effectively  lower  Lp(a).  Several  agents  are
urrently in  development  to  lower  Lp(a),  such  as  propro-
ein convertase  subtilisin/kexin  type  9  inhibitors,  antisense
ligonucleotides targeting  apolipoprotein  B,  and  microsomal
riglyceride transfer  protein  inhibitors.13--15
Early  detection  and  intervention,  preferably  before  the
nset of  atherosclerotic  CVD,  offers  the  best  opportunity
o reduce  the  time-dependent  risk  associated  with  this
1
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mportant  cardiovascular  risk  factor.  However,  it  should  not
e  forgotten  that  there  is  to  date  no  strong  clinical  evidence
hat lowering  Lp(a)  has  any  beneficial  effects  in  preventing
ardiovascular disease.
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